New cancer drug trial halted after just 3 patients
NCT ID NCT07159828
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called AXN-2510 in adults with advanced solid tumors that had stopped responding to other treatments. The drug is a special antibody that targets two cancer pathways at once. However, the study was terminated early after enrolling only 3 participants, so we have very little information about its safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AXN-2510 (a bispecific antibody that blocks PD-L1 and inhibits VEGF)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This was a very early, small Phase 1 trial that was terminated after only 3 participants. It is too early to know if the drug is safe or effective, and many early-stage cancer drugs never reach patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology
Huntersville, North Carolina, 28078, United States
-
NEXT Houston
Houston, Texas, 77054, United States
-
NEXT San Antonio
San Antonio, Texas, 78229, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
New Experimental Therapeutics (NEXT) Oncology - Houston
Houston, Texas, 77054, United States
-
New Experimental Therapeutics of San Antonio - NEXT Oncology
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, 75251, United States